Linda Yaccarino has been named CEO of eMed, a telehealth company specializing in GLP-1 medications such as Wegovy and Ozempic. This marks a significant shift from her previous career in marketing and media. Yaccarino's role comes at a crucial time as eMed aims to enhance chronic care access through a digital-first experience. She believes there is a substantial opportunity to leverage technology, lifestyle, and data to transform healthcare. Previously, eMed began its journey during the pandemic, providing COVID-19 tests and services before pivoting to weight loss drugs.
Yaccarino's transition to CEO at eMed aims to innovate chronic care access through a digital-first platform combining technology and lifestyle. Her extensive marketing experience is pivotal for expanding partnerships.
The healthcare industry is on the brink of transformation, according to Yaccarino, who emphasizes the need for combining technology with lifestyle and data in impactful, consumer-driven methods.
Collection
[
|
...
]